Billede af showet QCast: Data-Driven Dialogue in Drug Development

QCast: Data-Driven Dialogue in Drug Development

Podcast af Quanticate

engelsk

Videnskab & teknologi

Begrænset tilbud

1 måned kun 9 kr.

Derefter 99 kr. / månedOpsig når som helst.

  • 20 lydbogstimer pr. måned
  • Podcasts kun på Podimo
  • Gratis podcasts
Kom i gang

Læs mere QCast: Data-Driven Dialogue in Drug Development

QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.

Alle episoder

50 episoder

episode Episode 50: Multi-Omics Application in Personalised Medicine Studies cover

Episode 50: Multi-Omics Application in Personalised Medicine Studies

In this QCast episode, Jullia and Tom discuss multi-omics and its application in personalised medicine studies. The episode explains how genomic, transcriptomic, proteomic, metabolomic and other biological data layers can be analysed together to better understand disease, treatment response and patient subgroups. Key Takeaways * Multi-omics brings together several types of biological information to help researchers understand disease and treatment response more clearly than a single data layer can provide. * Multi-omics can support biomarker discovery, patient stratification and exploratory analysis, but findings need clear evidence before they can guide treatment, diagnosis or prevention. * Sample timing, visit labels, subject identifiers, protocol deviations and data quality checks all influence whether multi-omics data can be linked meaningfully to clinical outcomes. 🔗 Learn More & Get Support: Visit quanticate.com [https://quanticate.com] to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast [https://quanticate.com/podcast]. 🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode. About Quanticate Founded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in: * Clinical Data Capture & Management * Biostatistics & Statistical Consultancy * Statistical Programming & PK/PD Analysis * Medical Writing & Pharmacovigilance * Regulatory & Submission Support * AI & Automation * Post-Marketing Safety & Real-World Data Quanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.

12. juni 2026 - 10 min
episode Episode 49: BIMO Listings cover

Episode 49: BIMO Listings

In this QCast episode, Jullia and Tom discuss BIMO listings and their role in FDA inspection readiness. They explain how Bioresearch Monitoring looks at clinical trial conduct, participant protection, data credibility, and the records that support regulatory submissions. The episode also covers common misconceptions, including the idea that BIMO is only a site-level concern, and shows how sponsors can use inspection findings to strengthen oversight before issues become harder to resolve. Key Takeaways * BIMO oversight looks beyond final datasets. It considers how data was collected, reviewed, documented, and supported by source records. * BIMO listings can highlight patterns around protocol deviations, informed consent, adverse event reporting, data management, and submission readiness. * Good preparation depends on timely data entry, clear query handling, documented decisions, version control, and records that can be retrieved and explained. 🔗 Learn More & Get Support: Visit quanticate.com [https://quanticate.com] to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast [https://quanticate.com/podcast]. 🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode. About Quanticate Founded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in: * Clinical Data Capture & Management * Biostatistics & Statistical Consultancy * Statistical Programming & PK/PD Analysis * Medical Writing & Pharmacovigilance * Regulatory & Submission Support * AI & Automation * Post-Marketing Safety & Real-World Data Quanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.

5. juni 2026 - 10 min
episode Episode 48: Efficacy Endpoints in Oncology Clinical Trials cover

Episode 48: Efficacy Endpoints in Oncology Clinical Trials

In this QCast episode, Jullia and Tom discuss efficacy endpoints in oncology clinical trials and why endpoint choice shapes how treatment benefit is assessed. They look at overall survival, progression-free survival, objective response rate, disease-free survival, event-free survival, symptom endpoints, and quality-of-life measures. Key Takeaways * Overall survival remains one of the clearest measures of patient benefit, but it can require longer, larger trials and may be affected by treatments given after the study therapy. * Progression-free survival and objective response rate can show treatment activity earlier, but they answer different questions from overall survival. * Scan timing, missed assessments, censoring decisions, symptom questionnaires, and quality-of-life completion rates can all affect endpoint interpretation. 🔗 Learn More & Get Support: Visit quanticate.com [https://quanticate.com] to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast [https://quanticate.com/podcast]. 🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode. About Quanticate Founded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in: * Clinical Data Capture & Management * Biostatistics & Statistical Consultancy * Statistical Programming & PK/PD Analysis * Medical Writing & Pharmacovigilance * Regulatory & Submission Support * AI & Automation * Post-Marketing Safety & Real-World Data Quanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.

29. maj 2026 - 9 min
episode Episode 47: The Creation of ADaM Datasets for PK Analysis cover

Episode 47: The Creation of ADaM Datasets for PK Analysis

In this QCast episode, Jullia and Tom discuss how ADaM datasets are created for pharmacokinetic, or PK, analysis. They look at the role of ADPC for concentration data and ADPP for derived PK parameters, including how these datasets relate to SDTM PC and PP. The episode also covers why timing, dosing information, analysis values, flags and study-specific rules matter when preparing PK data for reporting and review. Key Takeaways * ADPC supports PK concentration data, while ADPP supports derived PK parameters such as Cmax, Tmax, AUC and half-life. Both datasets help turn PK data into an analysis-ready structure. * PK results depend on the relationship between dosing and sample collection. Planned and actual time points, relative time variables and pre-dose samples all need careful handling. * Analysis values, flags and criteria variables help show which records were analysed, which were excluded and why. This makes PK outputs easier to review and reproduce. 🔗 Learn More & Get Support: Visit quanticate.com [https://quanticate.com] to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast [https://quanticate.com/podcast]. 🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode. About Quanticate Founded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in: * Clinical Data Capture & Management * Biostatistics & Statistical Consultancy * Statistical Programming & PK/PD Analysis * Medical Writing & Pharmacovigilance * Regulatory & Submission Support * AI & Automation * Post-Marketing Safety & Real-World Data Quanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.

22. maj 2026 - 8 min
episode Episode 46: What is Clinical Data Review? cover

Episode 46: What is Clinical Data Review?

In this QCast episode, Jullia and Tom discuss clinical data review as an active part of study oversight, rather than a late-stage clean-up exercise. They explore how timely, connected review supports subject safety, data quality, medical review and confident decision-making, especially as trial data now comes from EDC, ePRO, eCOA, labs, imaging, biomarkers, wearables and other sources. Key Takeaways * Good review helps teams spot patterns, missing context and signals that may affect trial conduct or subject safety before issues become embedded. * A lab result, adverse event or dosing change becomes more useful when it can be reviewed alongside related data at the right point in the study. * Dashboards, alerts and automation can help focus attention, but teams still need clear ownership, escalation routes, traceability and risk-based priorities. 🔗 Learn More & Get Support: Visit quanticate.com [https://quanticate.com] to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast [https://quanticate.com/podcast]. 🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode. About Quanticate Founded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in: * Clinical Data Capture & Management * Biostatistics & Statistical Consultancy * Statistical Programming & PK/PD Analysis * Medical Writing & Pharmacovigilance * Regulatory & Submission Support * AI & Automation * Post-Marketing Safety & Real-World Data Quanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.

15. maj 2026 - 12 min
En fantastisk app med et enormt stort udvalg af spændende podcasts. Podimo formår virkelig at lave godt indhold, der takler de lidt mere svære emner. At der så også er lydbøger oveni til en billig pris, gør at det er blevet min favorit app.
En fantastisk app med et enormt stort udvalg af spændende podcasts. Podimo formår virkelig at lave godt indhold, der takler de lidt mere svære emner. At der så også er lydbøger oveni til en billig pris, gør at det er blevet min favorit app.
Rigtig god tjeneste med gode eksklusive podcasts og derudover et kæmpe udvalg af podcasts og lydbøger. Kan varmt anbefales, om ikke andet så udelukkende pga Dårligdommerne, Klovn podcast, Hakkedrengene og Han duo 😁 👍
Podimo er blevet uundværlig! Til lange bilture, hverdagen, rengøringen og i det hele taget, når man trænger til lidt adspredelse.

Vælg dit abonnement

Mest populære

Begrænset tilbud

Premium

20 timers lydbøger

  • Podcasts kun på Podimo

  • Ingen reklamer i podcasts fra Podimo

  • Opsig når som helst

1 måned kun 9 kr.
Derefter 99 kr. / måned

Kom i gang

Premium Plus

100 timers lydbøger

  • Podcasts kun på Podimo

  • Ingen reklamer i podcasts fra Podimo

  • Opsig når som helst

Prøv gratis i 7 dage
Derefter 129 kr. / måned

Prøv gratis

Kun på Podimo

Populære lydbøger

Ofte stillede spørgsmål

Flere spørgsmål og svar
Kom i gang

1 måned kun 9 kr. Derefter 99 kr. / måned. Opsig når som helst.